Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS
Tournier, A., Gavoille, A., Pique, J., Levraut, M., Micoud, E., Maillart, E., Audoin, B., Demortiere, S., Boutiere, C., Ayrignac, X., et al. (2026). Neurology (106). p.e214806

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study
Roos, I., Sharmin, S., Ozakbas, S., Alroughani, R., Eichau, S., Grand’Maison, F., Boz, C., Lechner-Scott, J., Buzzard, K., Prat, A., et al. (2026). CNS Drugs

Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Boudot de la Motte, M., Gavoille, A., Papeix, C., Audoin, B., Ayrignac, X., Bourre, B., Ciron, J., Cohen, M., Collongues, N., Laplaud, D.A., et al. (2026). JAMA Neurol

Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis
Rollot, F., Casey, R., Kerbrat, A., Edan, G., Le Page, E., Vukusic, S., Mathey, G., Maillart, E., De Sèze, J., Ciron, J., et al. (2026). Brain p.awag060

Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patients
Comet, C., Jouvenot, G., Bourre, B., Ciron, J., Audoin, B., Ayrignac, X., Cohen, M., Deschamps, R., Durand-Dubief, F., Maillart, E., et al. (2026). Mult Scler (32). p.214–223